← Back to Clinical Trials
Recruiting NCT07008664

NCT07008664 Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07008664
Status Recruiting
Phase
Sponsor University of Maryland, Baltimore
Condition Lung Cancer
Study Type OBSERVATIONAL
Enrollment 750 participants
Start Date 2025-03-31
Primary Completion 2031-04

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Epigenetic Signature Assay

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 750 participants in total. It began in 2025-03-31 with a primary completion date of 2031-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.

Eligibility Criteria

Inclusion Criteria: * 18 years old or older * Patient at University of Maryland Baltimore Washington Medical Center * Willing and able to consent to study procedures listed in the protocol * Ability to speak and understand English Exclusion Criteria: * Younger than 18 years old * Patient not cared for at University of Maryland Baltimore Washington Medical Center * Unable to consent to study procedures listed in the protocol * Unable to speak or understand English

Contact & Investigator

Central Contact

McKenzie Bedra, MPH

✉ McKenzie.Bedra@umm.edu

📞 410-553-8184

Frequently Asked Questions

Who can join the NCT07008664 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07008664 currently recruiting?

Yes, NCT07008664 is actively recruiting participants. Contact the research team at McKenzie.Bedra@umm.edu for enrollment information.

Where is the NCT07008664 trial being conducted?

This trial is being conducted at Glen Burnie, United States.

Who is sponsoring the NCT07008664 clinical trial?

NCT07008664 is sponsored by University of Maryland, Baltimore. The trial plans to enroll 750 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology